GlassScriptPhysician profile
Paul C Schwartz
NPI 1073583852
$6,189.75
in general payments reported to CMS, 2019-2025
28 companies · $627 in 2025
The $627 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $679 · 2021: $1,316 · 2022: $920 · 2023: $860 · 2024: $730 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.83 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.19 | 2019-2025 | Ubrelvy, Synthroid |
| Astellas Pharma US INC | $672.54 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $618.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $453.56 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.07 | 2020-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $301.70 | 2019-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $296.67 | 2020-2025 | |
| Exact Sciences Corporation | $259.24 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $234.60 | 2019-2022 | |
| Novo Nordisk INC | $233.39 | 2019-2025 | Wegovy |
| Amgen INC. | $207.26 | 2019-2021 | |
| Glaxosmithkline, LLC. | $206.54 | 2020-2024 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $149.47 | 2019-2024 | Eliquis |
| Esperion Therapeutics, INC. | $119.21 | 2020-2021 | |
| Horizon Therapeutics Plc | $118.25 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $106.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $95.54 | 2019-2025 | Spravato |
| Biohaven Pharmaceuticals, INC. | $87.80 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $70.00 | 2019-2021 | |
| Eisai INC. | $63.41 | 2021 | |
| Hikma Pharmaceuticals USA | $49.41 | 2019-2020 | |
| Sanofi Pasteur INC. | $42.99 | 2019-2023 | |
| Althera Pharmaceuticals LLC | $41.97 | 2021 | |
| Renalytix Ai, INC. | $38.62 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Idorsia Pharmaceuticals US INC | $38.34 | 2023 | Quviviq |
| Allergan, INC. | $37.12 | 2020 | |
| Abbott Laboratories | $21.40 | 2020 | |
| Lilly USA, LLC | $16.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.